![Placeholder Image Placeholder Image](https://prod1.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseNovartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
-
Media ReleaseNovartis erzielt im zweiten Quartal ein solides Wachstum und setzt die Transformation zu einem fokussierten Arzneimittelunternehmen fort
-
Media ReleaseNovartis réalise une solide croissance au deuxième trimestre et poursuit sa transformation en une entreprise axée sur les médicaments
-
Media ReleaseNovartis delivers solid growth in second quarter and continues transformation to a focused medicines company
-
Media ReleaseNovartis ernennt Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance Officer
-
Media ReleaseNovartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
-
Media ReleaseNovartis appoints Elizabeth Barrett as Oncology Head
-
Media ReleaseNovartis ernennt Elizabeth Barrett zur Chefin Onkologie
Pagination
- ‹ Previous page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- › Next page